18F-DOPA PET to Elucidate the Antidepressant Mechanism of Lurasidone in Bipolar Disorder
Status:
Completed
Trial end date:
2019-08-01
Target enrollment:
Participant gender:
Summary
The goal of this project is to understand what causes bipolar disorder and how medications
treat bipolar depression. Particularly, the project focuses on the importance of dopamine
signaling in the process. Participants will have two different brain scans (MRI and PET
scan). They will also have treatment for your depression with an FDA approved medication,
lurasidone (Latuda). The study is funded by the Columbia University Irving Institute to
improve the treatment of bipolar disorder.